A network approach to developing immuno-oncology combinations in Canada

Immune checkpoint inhibitors have revolutionized care for many cancer indications, with considerable effort now being focused on increasing the rate, depth, and duration of patient response. One strategy is to combine immune strategies (for example, ctla-4 and PD-1/L1–directed agents) to harness add...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Oncol
Main Authors: Higenell, V., Fajzel, R., Batist, G., Cheema, P.K., McArthur, H.L., Melosky, B., Morris, D., Petrella, T.M., Sangha, R., Savard, M.F., Sridhar, S.S., Stagg, J., Stewart, D.J., Verma, S.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2019
Assuntos:
Practice Guideline
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6476440/
https://ncbi.nlm.nih.gov/pubmed/31043804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4393
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados